40 results about "Hsp27" patented technology

A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and β-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.

UBC.P-031 Patent Application-Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.

The invention belongs to the field of application of feed additive, and relates to a porcine heat stress resistance selenium-rich composite bacteria feed additive and application thereof. Saccharomyces cerevisiae, lactobacillus acidophilus and streptococcus thermophilus are selected as strains, inoculated in a proper fermentation broth containing sodium selenite, transformation of selenium and probiotics growth accelerating agent in a volume ratio of 1:2:2, and fermented for 30 to 40 hours at a temperature of between 20 and 40 DEG C, throughput of 0.05m<3> / h, revolution of 70r / min and tank pressure of 0.04Mpa; and the selenium enriched composite bacteria preparation can be prepared through proper subsequent treatment. The daily gain and feed-weight ratio of a pig can be remarkably improved in a high-temperature environment by feeding the preparation, the oxidation resistance and immunity functions can be enhanced, the mRNA (messenger ribonucleic acid) level of heat shock proteins Hsp70 and Hsp27 can be reduced, and the effect of porcine heat stress resistance can be effectively played.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and beta-HCG.

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Cells expressingHsp27 exhibit reduced levels of p27kip1. Accordingly, a method for treatment of cancer using hsp27 inhibition that includes a preliminary test to ascertain the status of the p27kip1 in the target cells. In this test, a sample of cancerous tissue from the patient from the patient (including a human patient) and evaluated to determine an expression of level of functional p27kip1. In the case where the expression level of p27kip1 is below a threshold level, a therapeutic composition comprising as an active agent a composition effective to inhibit the expression or activity of hsp27 in administered to the patient.

Provided are methods for intra-operatively predicting, detecting or diagnosing the risk or onset of spinal cord ischemia and / or associated permanent paralysis in a patient, based upon the stress-induced elevation of levels of heat shock proteins, specifically HSP70 and / or HSP27 in the cerebral spinal fluid of the patient, as measured during thoracic-aorta surgery, particularly thoracic aneurysm repair surgery, that will permit intra-operative medical intervention to try to prevent or attenuate severe, and often fatal, complications. Further provided are kits, assay devices and methods of analyzing biomarker data for use in pre-, intra- or post-operatively detecting the stress-induced elevations of the measured levels of HSP70 and / or HSP27, and the biomarker itself.

Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.

The subject invention concerns materials and methods for treating neurodegenerative diseases and conditions associated with aggregation of the microtubule-associated protein tau. A method of the invention comprises administering an effective amount of a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a person or animal in need of treatment. In one embodiment, a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, is contacted with or provided to a target cell. The target cell can be a neuron. In a specific embodiment, an Hsp27 is delivered to the target cell via a polynucleotide encoding an Hsp27 protein, or a biologically-active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding an Hsp27 protein directly into neural tissue of a person or animal. The subject invention also concerns compositions comprising i) a heat shock protein 27, or a biologically-active fragment or variant thereof, and / or ii) a polynucleotide encoding an Hsp27, or a biologically-active fragment or variant thereof. The polynucleotide can be an expression construct that provides for expression of an Hsp27 in a target cell.

The invention discloses an application of Hsp27 in tolerance diagnosis and treatment for tongue cancer chemotherapy. The conditions that the Hsp27 protein level in a tongue cancer cell culture supernatant and the Hsp27 protein level in serum of a tongue cancer patient can be raised through chemotherapeutic drug treatment and expression of the Hsp27 in a tolerance cell for tongue cancer chemotherapy is higher than that in a sensitive cell are verified for the first time; and the chemosensitivity of a drug-resistant cell is improved by interfering with and lowering the expression of the Hsp27 and the chemotherapy tolerance of the tongue cancer cell is improved through overexpression of the Hsp27. New data is provided for research on a tolerance mechanism for tongue cancer chemotherapy, a new detection marker is provided for prediction of the tongue cancer chemosensitivity, and a theoretical basis is provided for development of a new treatment strategy based on the Hsp27 as a target.

The present invention pertains to the field of biotechnology and medicine and discloses a usage of Heat Shock Protein 27(HSP27) in the heart protection aspect. The present invention firstly reveals that the HSP27 gene can be applied in the specific myofilament protein for stabilizing ischemia, heart failure and other damages of the heart muscle, so as to improve the contractile function of the heart muscle; the present invention also proves that the HSP27 transfected by the adenovirus vector can improve the contractile function of the heart with ischemia and can provide an effective new target for the treatment of heart diseases.

A method of preventing or treating cardiovascular disease is provided. The method comprises administering heat shock protein 27 (HSP27), a co-factor, variant or analogue thereof. The cardiovascular disease can include atherosclerosis. A pharmaceutical composition comprising HSP27 for use in the prevention or treatment of cardiovascular disease is also provided.

The invention relates to the heat shock protein (HSP) 27 medical using. The invention uses the method of protein groupology to take animal mould experiment show that the HSP27 highly expressed. Immunohistochemistry testing result shows HSP27 locating in the liver cell cytoplasm; blood serum protein groupology found that HSP27 is owned by liver cancer; the Western Blot identification result shows HCC patient has strong HSP27(100%, 20 / 20); blood serum double blind testified normal blood serum do not display HSP27(0 / 10), HCC patient positive incidence is 100%(30 / 30). The result shows HSP27 protein could be used as the marking material protein to testing liver cancer. It could be used to make predict and diagnose medicine containing AFP negative HCC and the transformation.

The invention provides a fused protein as well as a preparation method and application thereof. The fused protein comprises a CLIC1 protein, a connecting peptide and an Hsp27 (Heat Shock Proteins 27) protein; and the CLIC1 protein is connected with the Hsp27 protein through the connecting peptide. The fused protein provided by the invention can be applied to preparation of medicines for preventing and treating tumors and has the advantages of good specificity, high efficiency of antigens and the like.

The invention discloses recombinant fusion protein PTP-HSP27 and use thereof; an amino acid sequence is SEQ ID NO.1; the recombinant fusion protein PTP-HSP27 disclosed by the invention not only has the biological activity of HSP27, but also has a transcellular barrier transportation function; the recombinant fusion protein PTP-HSP27 can effectively perforate into lenticular epithelial cells (LEC); the apoptosis of the lenticular epithelial cells is alleviated; and the development and progression of cataract is delayed greatly. According to the invention, the recombinant fusion protein PTP-HSP27 endows the transcellular barrier transportation function of PTD to the HSP27, thus, the HSP27 easily perforates the cell barrier of corneas and effectively enters eyes through cornea tissues; and the application range of the recombinant fusion protein PTD-HSP27 in an eye part is expanded.

The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.

A method for detection or monitoring status of traumatic brain injury (TBI) or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP), or a trauma-specific break down product (BDP) of ALDOC or BLBP. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. The method can comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a cleavage product of ALDOC, GS, PEA15, or CRYAB, or a combination of two or more thereof.

The invention discloses a biological insecticide screening mode, which comprises the following steps: integrating acceptor EcR with ecdysone GAP with gene expressing box Promoter-EcR-AOX1 TT and super spiral protein USP gene with gene expressing box TEF1 Promoter-USP-CYC1 TT on the colorant layer of Pasteur pichia; integrating DNA fragment with fruit fly 5XEcRE-HSP27 Promoter-GFP on the colorant layer yeast; getting the product. To co-culture screening drug with this product, we can get stopping or reinforcing GFP expression biological insecticide.

The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27. In addition, the present invention relates to a method for screening for active substances for promoting angiogenesis or for active substances for treating an angiogenesis-dependent ailment, the method comprising the following steps: treating vascular endothelial cell lines with each specimen; measuring the content of HSP27 in the respective vascular endothelial cell lines; and selecting a specimen in which the HSP27 content in the vascular endothelial cell lines are decreased as compared to a control group.

The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.

Provided is an application of an artificially expressed HSP27 protein in detecting β2-adrenergic receptor stimulant drug residue.

The purpose of the present invention is to provide a novel evaluation method which, without being burdensome to a user, is capable of evaluating the degree of skin stress accumulation and further of simply and reliably evaluating whether the skin is sensitive. To this end, the degree of stress accumulation is evaluated by non-invasively sampling the stratum corneum by means of tape stripping, etc., and by assaying the expression level of HSP27 contained therein.

Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.

The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented.General formula of these compounds is formula (I):as further defined in claim 1.